Ambrx Biopharma Cayman, Inc. financial data

Location
10975 North Torrey Pines Road, La Jolla, CA
Fiscal year end
December 31

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 434M shares
Common Stock, Shares, Outstanding 432M shares +59.9%
Common Stock, Value, Issued 43K USD +59.3%
Weighted Average Number of Shares Outstanding, Basic 391M shares +44.8%
Weighted Average Number of Shares Outstanding, Diluted 391M shares +44.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.12M USD -13.5%
Revenue from Contract with Customer, Excluding Assessed Tax 1.12M USD -13.5%
Research and Development Expense 14.4M USD -20.3%
General and Administrative Expense 5.9M USD +22.3%
Operating Income (Loss) -19.2M USD +33.4%
Nonoperating Income (Expense) 1.65M USD +2325%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.5M USD +39%
Income Tax Expense (Benefit) 305K USD +136%
Net Income (Loss) Attributable to Parent -17.8M USD +38.2%
Earnings Per Share, Basic -0.05 USD/shares +54.5%
Earnings Per Share, Diluted -0.05 USD/shares +54.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 228M USD +248%
Accounts Receivable, after Allowance for Credit Loss, Current 81K USD -94.5%
Other Assets, Current 981K USD -0.51%
Assets, Current 241M USD +99.5%
Property, Plant and Equipment, Net 3.2M USD +1.56%
Operating Lease, Right-of-Use Asset 10M USD -15.3%
Intangible Assets, Net (Excluding Goodwill) 24.9M USD -2.46%
Other Assets, Noncurrent 357K USD -23.4%
Assets 280M USD +54.8%
Accounts Payable, Current 6.36M USD +11.7%
Accrued Liabilities, Current 9.56M USD -38.7%
Liabilities, Current 18.2M USD -29.4%
Contract with Customer, Liability, Noncurrent 1.75M USD -58.8%
Deferred Income Tax Liabilities, Net 880K USD 0%
Operating Lease, Liability, Noncurrent 9.16M USD -18.6%
Liabilities 29.6M USD -24.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -953K USD +5.36%
Retained Earnings (Accumulated Deficit) -325M USD -22.5%
Stockholders' Equity Attributable to Parent 250M USD +76.5%
Liabilities and Equity 280M USD +54.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13M USD +49.5%
Net Cash Provided by (Used in) Financing Activities 77.2M USD
Net Cash Provided by (Used in) Investing Activities 29.6M USD
Common Stock, Shares Authorized 950M shares +90%
Common Stock, Shares, Issued 432M shares +59.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 93.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 229M USD +244%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Depreciation 200K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Property, Plant and Equipment, Gross 9.22M USD +10%
Operating Lease, Liability, Current 1.85M USD +40.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Preferred Stock, Shares Issued 0 shares
Operating Lease, Payments 673K USD +227%
Additional Paid in Capital 576M USD +41.2%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 200K USD -50%
Share-based Payment Arrangement, Expense 2.89M USD +53.6%